Home/Stocks/BDX
Public stock intelligence

Becton, Dickinson and Company with price, financials, news flow, and insider context in one page.

Becton, Dickinson and Company is being tracked here through price action, operating context, and headline flow. This public page covers the latest market move, where BDX sits inside Healthcare and Medical Instruments & Supplies, and the key financial markers that matter before moving into a fuller research workflow.

HealthcareMedical Instruments & SuppliesNYQUnited States
Live price
$143.45
Session move
-2.75% today
Next earnings
Aug 6, 2026
Market cap
39.51B
Volume
2.82M
52-week range
27% through the 52-week range
Forward P/E
10.66
Revenue growth
5.2%
Dividend yield
100.0%
Price history
Daily closes for BDX, with a quick range selector for public research.
About the company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. It operates through Medical Essentials, Connected Care, BioPharma Systems, Interventional and Life Sciences segments. It provides peripheral intravenous (IV) and advanced peripheral catheters, central lines, acute dialysis catheters, vascular access technology, vascular care and preparation products, needle-free IV connectors and extensions sets, closed-system drug transfer devices, hazardous drug detections, hypodermic syringes and needles, anesthesia needles and trays, enteral syringes, and sharps disposal systems; IV medication safety and infusion therapy delivery systems, medication compounding workflow system, automated medication dispensing and supply management systems, informatics and analytics and pharmacy automation system, and medication inventory optimization and tracking system; hemodynamic monitoring system; and prefillable drug delivery systems. It also offers specimen and blood collection products; automated blood and tuberculosis culturing, molecular testing, and microorganism identification and drug susceptibility, as well as rapid diagnostic assays, microbiology laboratory automation products, and plated media products; and fluorescence-activated cell sorters and analyzers, antibodies and kits, reagent system, and solution for single-cell gene expression analysis, as well as clinical oncology, immunological, and transplantation diagnostic/monitoring reagents and analyzers. It provides hernia and soft tissue repair, biological and bioresorbable graft, biosurgery, and other surgical products; surgical infection prevention, peripheral intervention, and urology and critical care products. The company has a strategic collaboration with ChemoGLO for the advancement of hazardous drug contamination testing in health care settings to improve the safety of health care workers. The company was founded in 1897 and is headquartered in Franklin Lakes, New Jersey.

Employees
60,000
Beta
0.29
ROE
6.7%
Current ratio
0.94
Visit company website
Research framing

This page is structured for research context, not a trade call. It gives you a clean read on where BDX sits in its range, what the last few quarters look like, and which headlines are shaping attention.

For position sizing, alerts, saved watchlists, and deeper analysis workflows, the next step is the logged-in Meridian workspace.

Quarterly financials
QuarterRevenueNet incomeFree cash flow
Q4 20255.25B382M548M
Q3 20255.89B493M1B
Q2 20255.51B574M1.05B
Q1 20255.27B308M35M
Insider activity
ROQUE VITOR
Chief Financial Officer
May 7, 2026
Transaction
Stock Award(Grant) at price 0.00 per share.
Value
N/A
FELD MICHAEL
Officer
Apr 27, 2026
Transaction
Sale at price 151.94 per share.
Value
11.24K
FELD MICHAEL
Officer
Mar 26, 2026
Transaction
Sale at price 156.83 per share.
Value
11.76K
MINNIX LANESHA
General Counsel
Mar 16, 2026
Transaction
Stock Award(Grant) at price 0.00 per share.
Value
N/A
SPIKNER PAMELA L
Officer
Mar 2, 2026
Transaction
Stock Award(Grant) at price 0.00 per share.
Value
N/A
ROQUE VITOR
Chief Financial Officer
Mar 2, 2026
Transaction
Stock Award(Grant) at price 0.00 per share.
Value
N/A
Why this page ranks

A public stock page should answer the first research questions before asking for a signup.

This BDX page is designed for public research utility. You can read the latest session move, check the one-year chart, review a compact financial table, scan recent headlines, and compare adjacent names without immediately moving into a gated dashboard.

The logged-in Meridian workflow goes further with saved watchlists, deeper analysis, alert routing, and recurring review systems. The public layer is meant to be credible and indexable on its own, not a hollow teaser page.